Financial Performance - Aurinia Pharmaceuticals Inc. reported total revenue of $77.1 million for Q4 2025, a 29% increase from $59.9 million in Q4 2024, and $283.1 million for the full year 2025, up 20% from $235.1 million in 2024 [1] - Net product sales of LUPKYNIS reached $74.2 million for Q4 2025, a 29% increase from $57.6 million in Q4 2024, and $271.3 million for the full year 2025, up 25% from $216.2 million in 2024 [2] Cash Position and Share Repurchase - As of December 31, 2025, Aurinia had cash, cash equivalents, restricted cash, and investments totaling $398.0 million, an increase from $358.5 million in the prior year [3] - The company repurchased 12.2 million common shares for $98.2 million during 2025 [3] Future Outlook - For 2026, Aurinia expects total revenue between $315 million and $325 million, representing an 11% to 15% increase compared to 2025, and net product sales between $305 million and $315 million, up 12% to 16% from 2025 [3] Company Overview - Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of therapeutic drugs [4]

Core Insights - Aurinia Pharmaceuticals reported significant growth in revenue and net income for the full year 2025, driven primarily by its lupus nephritis therapy, LUPKYNIS [4][6][7] Financial Performance - Total revenue for the full year 2025 was $283.1 million, a 20% increase from $235.1 million in 2024; excluding a one-time $10 million milestone payment, revenue increased by 26% year over year [1][6] - Full-year net product sales of LUPKYNIS reached $271.3 million, up 25% from $216.2 million in 2024 [1] - In Q4 2025, net income surged to $210.8 million from $1.4 million in the same quarter of the previous year, largely due to a $175.1 million income tax benefit [2][6] - Diluted earnings per share for 2025 were $2.07, up from $0.04 in 2024 [7] Revenue Breakdown - Q4 2025 revenue was $77.1 million, a 29% increase from $59.9 million in Q4 2024; net product sales of LUPKYNIS in the quarter were $74.2 million, also up 29% [3][6] - Management provided guidance for 2026, expecting total revenue of $315 million to $325 million, representing 11% to 15% growth compared to 2025 [9] Pipeline and Clinical Development - Aurinia has initiated clinical development of aritinercept, a dual BAFF/APRIL inhibitor, with two studies planned for H1 2026 [5][16] - The pediatric VOCAL study was terminated due to recruitment challenges, and the company plans to negotiate with the FDA regarding pediatric commitments in lupus nephritis [18] Commercial Dynamics - The company is seeing growth in patient adherence and consistency in the mix of business, with a favorable prescriber mix leaning slightly towards rheumatology [11][12] - Management noted that guideline-driven improvements in diagnostics and treatment for lupus nephritis have room for expansion, with current practices not fully aligning with recommended guidelines [13][14] Competitive Landscape - Despite the approval of Gazyva for lupus nephritis, Aurinia has not observed a near-term impact on its business performance [14] - LUPKYNIS is positioned competitively due to its efficacy in reducing proteinuria rapidly compared to other therapies [15]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $77.1 million, up 29% from $59.9 million in Q4 2024 [4] - Net product sales of LUPKYNIS for Q4 2025 were $74.2 million, up 29% from $57.6 million in Q4 2024 [4] - Net income for Q4 2025 was $210.8 million, up 14,957% from $1.4 million in Q4 2024, primarily due to a significant income tax benefit [4] - Diluted earnings per share for Q4 2025 was $1.53, up 15,200% from $0.01 in Q4 2024 [5] - Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% from $235.1 million in 2024 [6] - Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024 [6] Business Line Data and Key Metrics Changes - Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024 [6] - Cash flows from operating activities for Q4 2025 were $45.7 million, up 52% from $30.1 million in Q4 2024 [5] - Cash flows from operating activities for the year ended December 31, 2025, were $135.7 million, up 206% from $44.4 million in 2024 [7] Market Data and Key Metrics Changes - The company expects net product sales of $305 million to $315 million for 2026, representing a 12%-16% increase compared to 2025 [3][8] - The company repurchased 12.2 million common shares for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million [7] Company Strategy and Development Direction - The company is focused on the growth of LUPKYNIS while advancing the clinical development of aritinercept, a novel biologic for autoimmune diseases [9][10] - The strategy includes leveraging data on the efficacy of LUPKYNIS and promoting early diagnosis and treatment of lupus nephritis [14][27] - The company aims to change the treatment paradigm by emphasizing the importance of early identification and aggressive treatment of proteinuria [14][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of LUPKYNIS, citing strong adherence and persistency among patients [24] - The management acknowledged the competitive landscape but emphasized the unique benefits of LUPKYNIS, particularly its speed in reducing proteinuria [36][38] - The company does not expect significant contributions from international markets compared to the U.S. due to varying pricing and reimbursement structures [42][43] Other Important Information - The company terminated the phase 3 VOCAL study due to recruitment challenges and plans to negotiate with the FDA regarding pediatric commitments [16][17] - Management is optimistic about the potential of aritinercept and plans to initiate clinical studies in additional autoimmune diseases in 2026 [10][22] Q&A Session Summary Question: Guidance for 2026 seems conservative; what are the underlying assumptions? - Management explained that the guidance is based on historical growth patterns and current market conditions, with no extraordinary trends observed in early 2026 [12][15] Question: Clarification on the termination of the VOCAL study and FDA's stance? - The study was terminated due to recruitment difficulties, and management plans to discuss pediatric commitments with the FDA [16][17] Question: Update on AURINIAcept development? - Management confirmed that updates will be provided in the second quarter of 2026, with no preferential indication currently identified [20][50] Question: Impact of Gazyva's approval on LUPKYNIS? - Management stated that there has been no immediate impact on LUPKYNIS sales, and the guidance incorporates various competitive factors [34][35] Question: Are doctors combining B-cell and T-cell therapies? - Management noted that there is potential for combining therapies, and discussions are ongoing regarding the efficacy of such combinations [45][46]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $77.1 million, up 29% from $59.9 million in Q4 2024 [4] - Net product sales of LUPKYNIS for Q4 2025 were $74.2 million, up 29% from $57.6 million in Q4 2024 [4] - Net income for Q4 2025 was $210.8 million, up 14,957% from $1.4 million in Q4 2024 [4] - Diluted earnings per share for Q4 2025 was $1.53, up 15,200% from $0.01 in Q4 2024 [5] - Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% from $235.1 million in 2024 [6] - Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024 [6] Business Line Data and Key Metrics Changes - Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024 [6] - Cash flows from operating activities for Q4 2025 were $45.7 million, up 52% from $30.1 million in Q4 2024 [5] - Cash flows from operating activities for the year ended December 31, 2025, were $135.7 million, up 206% from $44.4 million in 2024 [7] Market Data and Key Metrics Changes - The company expects net product sales of $305 million to $315 million for 2026, representing a 12%-16% increase compared to 2025 [3][8] - The company repurchased 12.2 million common shares for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million [7][8] Company Strategy and Development Direction - The company is focused on the commercial growth of LUPKYNIS while advancing the clinical development of aritinercept, a novel biologic for autoimmune diseases [9][10] - The strategy includes leveraging data on the efficacy of LUPKYNIS and promoting early diagnosis and treatment of lupus nephritis [14][27] - The company aims to change the treatment paradigm by emphasizing the importance of early identification and aggressive treatment of proteinuria [14][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of LUPKYNIS, citing strong adherence and persistency among patients [24] - The company acknowledged the competitive landscape with the introduction of Gazyva but noted no immediate impact on LUPKYNIS sales [35] - Management emphasized the importance of awareness and aggressive treatment in growing the market for lupus nephritis [36] Other Important Information - The company terminated the phase III VOCAL study due to recruitment challenges and plans to negotiate with the FDA regarding pediatric commitments [16][17] - Management highlighted the potential for combining B-cell and T-cell therapies in treating lupus nephritis, indicating ongoing research in this area [46][47] Q&A Session Summary Question: Guidance for 2026 seems conservative; what are the underlying assumptions? - Management explained that the guidance is based on historical growth patterns and current market conditions, with no extraordinary trends observed in early 2026 [12][15] Question: Clarification on the termination of the VOCAL study and FDA's stance? - Management clarified that the study was terminated due to recruitment difficulties and that they plan to discuss pediatric commitments with the FDA [16][17] Question: Update on aritinercept development and study design? - Management confirmed that a clinical study for aritinercept has been initiated, with more details expected in Q2 2026 [20][22] Question: Impact of Gazyva's approval on LUPKYNIS? - Management stated that there has been no immediate impact on LUPKYNIS sales and that the guidance incorporates various factors, including competition [35][36] Question: Are doctors combining B-cell and T-cell therapies? - Management indicated that there is potential for combining therapies and that they are exploring this in ongoing research [46][47]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $77.1 million, up 29% from $59.9 million in Q4 2024 [3] - Net product sales of LUPKYNIS for Q4 2025 were $74.2 million, up 29% from $57.6 million in Q4 2024 [3] - Net income for Q4 2025 was $210.8 million, up 14,957% from $1.4 million in Q4 2024, primarily due to a significant income tax benefit [3][4] - Diluted earnings per share for Q4 2025 was $1.53, up 15,200% from $0.01 in Q4 2024 [4] - Total revenue for the year ended December 31, 2025, was $283.1 million, up 20% from $235.1 million in 2024 [5] - Net income for the year ended December 31, 2025, was $287.2 million, up 4,852% from $5.8 million in 2024 [5][6] - Cash flows from operating activities for the year ended December 31, 2025, were $135.7 million, up 206% from $44.4 million in 2024 [6] Business Line Data and Key Metrics Changes - Net product sales of LUPKYNIS for the year ended December 31, 2025, were $271.3 million, up 25% from $216.2 million in 2024 [5] - The company repurchased 12.2 million common shares for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million [6][7] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $305 million and $315 million, representing a 12%-16% increase compared to 2025 [2][7] - Total revenue guidance for 2026 is projected to be between $315 million and $325 million, up 11%-15% from 2025 [7] Company Strategy and Development Direction - The company is focused on the growth of LUPKYNIS while advancing the clinical development of aritinercept, a novel biologic for autoimmune diseases [9][10] - The strategy includes leveraging data on the efficacy of LUPKYNIS and promoting early diagnosis and treatment of lupus nephritis [14][27] - The company aims to change the treatment paradigm by emphasizing the importance of early identification and aggressive treatment of proteinuria [14][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of LUPKYNIS, citing strong adherence and persistency among patients [24] - The company acknowledged the competitive landscape with the recent approval of Gazyva but noted no immediate impact on LUPKYNIS sales [34] - Management emphasized the importance of awareness and guideline adoption to improve patient outcomes in lupus nephritis treatment [35][36] Other Important Information - The company has initiated a clinical study of aritinercept in one autoimmune disease and plans to start another study in the first half of 2026 [9][10] - Management indicated that the pediatric lupus nephritis market is small, and the business opportunity in this segment is limited [19] Q&A Session Summary Question: 2026 guidance seems conservative; what are the underlying assumptions? - Management reiterated that the growth strategy for LUPKYNIS remains consistent, focusing on efficacy data and early treatment [12][13] Question: Clarification on the termination of the VOCAL study and FDA interactions? - The VOCAL study was terminated due to recruitment challenges, and the company plans to negotiate with the FDA regarding pediatric commitments [17][18] Question: Update on AURINIAcept development? - Management confirmed that updates on AURINIAcept will be provided in the second quarter of 2026, with no preferential indication at this time [21][22] Question: What is driving the strong performance of LUPKYNIS? - Management noted growth across patients, solid adherence, and a favorable mix of business contributing to continued strong performance [24] Question: Impact of Gazyva's approval on LUPKYNIS? - Management stated that there has been no near-term impact from Gazyva's launch, and guidance incorporates various factors including competition [34][35]

Core Insights - Tang Capital Management has increased its stake in Aurinia Pharmaceuticals by acquiring 1.3 million shares, raising its total holding to 11.3 million shares valued at $125.2 million as of September 30 [2][4] - Aurinia's flagship product, LUPKYNIS, has shown significant growth, with net product sales increasing by 27% to $70.6 million, contributing to a quarterly revenue of $73.5 million, an 8% year-over-year increase [5][6] - The company has raised its full-year revenue guidance to between $275 million and $280 million, reflecting strong market uptake and operational efficiency improvements [6][7] Company Overview - Aurinia Pharmaceuticals is a commercial-stage biotechnology company focused on developing treatments for serious diseases, particularly autoimmune conditions, with a market capitalization of $2.1 billion [4] - The company reported a total revenue of $265.8 million and a net income of $77.8 million for the trailing twelve months (TTM) [4] - Aurinia's strategic collaborations, such as with Otsuka Pharmaceutical Co., enhance its competitive position in the biopharmaceutical sector [4] Financial Performance - Aurinia's third-quarter revenue of $73.5 million represents an 8% increase year-over-year, driven by strong sales of LUPKYNIS [5][6] - The company achieved a net income of $31.6 million in the third quarter, more than doubling the previous year's result [6] - Cash flows from operations increased significantly to $44.5 million, indicating improved operational efficiency [6]

Core Insights - Aurinia Pharmaceuticals is generally favored over PMV Pharmaceuticals based on a comparison of various financial and operational metrics, outperforming PMV in 10 out of 13 factors analyzed [10]. Analyst Ratings - Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 12.67%, while PMV Pharmaceuticals has a target price of $5.00, indicating a potential upside of 278.79% [2]. Risk & Volatility - Aurinia Pharmaceuticals has a beta of 1.3, indicating its share price is 30% more volatile than the S&P 500, whereas PMV Pharmaceuticals has a beta of 1.54, meaning its share price is 54% more volatile than the S&P 500 [3][4]. Institutional and Insider Ownership - 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors, compared to 90.2% for PMV Pharmaceuticals. Insider ownership stands at 12.2% for Aurinia and 7.6% for PMV [5]. Profitability - Aurinia Pharmaceuticals has a net margin of 23.31%, return on equity of 20.06%, and return on assets of 13.81%. PMV Pharmaceuticals does not have net margin data available, with a return on equity of -55.34% and return on assets of -51.01% [7]. Earnings and Valuation - Aurinia Pharmaceuticals reported gross revenue of $265.81 million, a net income of $5.75 million, and earnings per share of $0.56, with a price-to-earnings ratio of 28.00. PMV Pharmaceuticals has no revenue reported, a net loss of $58.71 million, earnings per share of -$1.60, and a price-to-earnings ratio of -0.83 [9].

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $73.5 million, an increase of 8% from $67.8 million in Q3 2024. Excluding a one-time milestone payment in 2024, total revenue increased by 27% year-over-year [4][5] - Net product sales of LUPKYNIS were $70.6 million, up 27% from $55.5 million in 2024 [4] - Net income was $31.6 million, up 119% from $14.4 million in 2024, with diluted earnings per share at $0.23, up 130% from $0.10 in 2024 [4] - Cash flows from operating activities were $44.5 million, up 162% from $17 million in 2024 [4] Business Line Data and Key Metrics Changes - LUPKYNIS sales grew at a rate of 27% year-over-year, prompting the company to raise its sales guidance for 2025 to $265 million-$270 million [3][6] - For the nine months ended September 30, 2025, net product sales of LUPKYNIS were $197.2 million, up 24% from $158.6 million in 2024 [5] Company Strategy and Development Direction - The company is focused on advancing its Atenercept program toward clinical studies in two autoimmune diseases, following positive phase one results [3][12] - The strategy includes sharpening commercial focus on high-volume prescribers, particularly rheumatologists, to drive growth in LUPKYNIS sales [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, citing positive momentum from the ACR guidelines and consistent performance in sales [26][49] - The company anticipates further details on the APRIL/BAF program to be disclosed in early 2026, indicating ongoing development and strategic planning [25][42] Other Important Information - The company filed a complaint against Dr. George Tidmarsh regarding statements about BacloSporin, which is pending in court [2] - New analyses of LUPKYNIS data reinforce its clinical profile, showing a 53% reduction in the risk of renal-related events or death [8] Q&A Session Summary Question: Insights on prescriber habits and LUPKYNIS usage - Management noted consistent growth in rheumatology prescribers and emphasized the positive impact of ACR guidelines on treatment practices [16][19] Question: Trends into Q4 and confidence in growth - Management expressed confidence in continued positive momentum for LUPKYNIS and plans to disclose more about the APRIL/BAF program in early 2026 [26][25] Question: FDA information request details - Management could not specify the trigger for the FDA's information request but emphasized the favorable data presented [32][41] Question: Persistence trends for LUPKYNIS - Management reported an upward trend in patient persistence on LUPKYNIS, supported by positive clinical data [55] Question: Atenercept dosing in clinical trials - Management confirmed that 150 mg dosing will be used in future studies, with further details to be disclosed in 2026 [62]

Core Insights - Several healthcare and biotech stocks experienced significant price movements on September 29, driven by clinical trial updates, regulatory progress, and strategic announcements Company Performance Highlights - Phio Pharmaceuticals Corp. (PHIO) saw an 8.9% increase in after-hours trading, rising from $2.36 to $2.57, following a 5.83% gain during the regular session, attributed to a positive safety committee recommendation for its PH-762 skin cancer trial [1][2] - Barinthus Biotherapeutics plc (BRNS) rose 8.11% in after-hours trading to $1.60 after closing at $1.48, with a notable 21.3% gain, driven by renewed interest in its immunotherapeutic pipeline [2][3] - Neogen Corp. (NEOG) jumped 5.59% in after-hours trading to $5.90, reversing a 1.41% decline earlier in the day, following announcements of its upcoming earnings release and a renewed sponsorship agreement [3][4] - OKYO Pharma Ltd. (OKYO) increased by 9% in after-hours trading to $2.18 after a decline of 8.26% during the regular session, due to renewed focus on its clinical-stage program for urcosimod [5] - Aurinia Pharmaceuticals Inc. (AUPH) rose 8.05% in after-hours trading to $11.95, despite a 15.83% drop earlier, reflecting heightened activity around its lupus nephritis treatment, LUPKYNIS, and a collaboration with Otsuka Pharmaceutical [6] - RAPT Therapeutics, Inc. (RAPT) climbed 4.43% in after-hours trading to $27.80, following the FDA's clearance of its IND application for RPT904, allowing it to proceed with a Phase 2b trial targeting food allergies [7][8]

Company Highlights - Aurinia Pharmaceuticals Inc. (AUPH) has seen solid growth for its product LUPKYNIS, with expected net product sales for 2025 ranging from $250 million to $260 million, up from $216.2 million last year [2][3] - Arrowhead Pharmaceuticals Inc. (ARWR) is preparing for its first commercial launch in 2025, with its lead drug candidate Plozasiran under FDA review, decision expected on November 18, 2025 [4][5] - Beta Bionics Inc. (BBNX) reported a 54% growth in second-quarter net sales, with expectations for full-year 2025 net sales to range between $88 million and $93 million, compared to $65.1 million last year [7][8] - Kiniksa Pharmaceuticals International plc (KNSA) anticipates net product revenue for its drug Arcalyst to be between $625 million and $640 million for 2025, up from $417 million in 2024 [10][11] - Ionis Pharmaceuticals Inc. (IONS) generated net product sales of $19 million in Q2 2025, with a supplemental new drug application expected by year-end [12][14] - Stoke Therapeutics Inc. (STOK) is developing Zorevunersen for Dravet syndrome, with a 52-week high of $24.60 reached recently, representing an 82% gain in less than two months [16][17] - Fortress Biotech Inc. (FBIO) is awaiting an FDA decision on its investigational drug CUTX-101 for Menkes disease, expected on September 30, 2025 [18][21] Stock Performance - AUPH stock increased by 168% over 1.5 years, reaching a 52-week high of $12.87 [3] - ARWR stock gained 65% in less than 9 months, hitting a 52-week high of $31.13 [5] - BBNX stock rose nearly 55% in less than 4 months, reaching a 52-week high of $26.66 [8] - KNSA stock saw a 46% increase in less than four months, touching a 52-week high of $37.34 [11] - IONS stock gained 52% in less than two months, reaching a 52-week high of $64.72 [15] - STOK stock increased by 82% in less than two months, achieving a 52-week high of $24.60 [17] - FBIO stock rose by 61% in less than a month, reaching a 52-week high of $3.97 [21]